Этелкальцетид в лечении вторичного гиперпаратиреоза у пациентов на программном гемодиализе: обзор клинических данных и место в терапии.

Г.В. Волгина, Н.А. Михайлова

Research output: Contribution to journalArticle

Abstract

Secondary hyperparathyroidism (SHPT) is common in patients receiving maintenance hemodialysis (MHD) and is associated with adverse outcomes. Currently, SHPT is managed by reducing circulating levels of phosphate with oral binders and parathyroid hormone (Pth) with vitamin d analogs and/or the calcimimetic cinacalcet (CC). This article provides a brief overview of the pathogenesis of SHPT in CKD, with particular attention paid to the main molecular regulators that are affected by calcimimetics. Etelcalcetide (EC) is a new second-generation calcimimetic administered intravenously (IV) at the end of a hemodialysis treatment session, effectively reduces pth in clinical trials when given thrice weekly. apart from improving drug adherence, EC has proven to be more effective in lowering pth when compared to cc, with an acceptable and comparable safety profile. Additional clinical effects include reductions in circulating levels of phosphate and FGF-23 and an improved profile of markers of bone turnover. however, des
Original languageRussian
Pages (from-to)74-83
JournalКЛИНИЧЕСКАЯ НЕФРОЛОГИЯ
Issue number2
StatePublished - 2020
Externally publishedYes

Keywords

  • calcimimetic
  • chronic kidney disease
  • dialysis
  • etelcalcetide
  • secondary hyperparathyroidism
  • вторичный гиперпаратиреоз
  • диализ
  • кальцимиметик
  • хроническая болезнь почек
  • этелкальцетид

Cite this